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ABSTRACT
The incidence of post-menopausal osteoporosis is increasing globally. In post-menopausal osteoporosis, there is deficiency 
in oestrogen level resulting in bone loss and fractures. Bone formation is under the control of different hormones. In 
the present review, we highlight few pathways such as RANKL/RANK, apoptosis and Wnt/β-catenin signalling pathways 
and phytoestrogens involved in the bone metabolism. RANKL/RANK signalling is responsible for regulating the formation 
and activation of multinucleated osteoclasts from their precursors which is responsible for the survival of normal bone 
remodelling. Apoptosis regulates the development, growth and maintains the bone tissues. The Wnt pathway is an important 
pharmacological target for bone anabolic drugs and its future discovery. In today’s world, herbal remedies are used 
to treat post-menopausal osteoporosis as these products contain phytoestrogens. These phytoestrogens are oestrogen 
like compounds which influence bone metabolism. The phytoestrogens provide better therapeutic effect in reducing the 
RANKL, osteoclastogenesis, inflammatory markers, and increase the osteogenic markers in the bone cells or osteoblasts. 
We discuss the mechanism of action of few phytoestrogens such as genistein, daidzein and equol which are beneficial 
for improvement of the bone health. Daidzein enhances osteoblast growth via the upregulation of BMP expression in 
primary osteoblast cells and it is a potential antiosteoporotic agent. Genistein also possesses antioestrogenic property 
by virtue of its competitive binding to the same receptors as oestradiol. Equol regulates the bone loss via hemopoiesis 
and inflammatory cytokine production. Thus, phytoestrogens could be efficiently used as osteoprotective agents for the 
treatment of individuals with post-menopausal osteoporosis. 
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ABSTRAK
Kejadian osteoporosis selepas menopaus meningkat secara global. Dalam osteoporosis selepas menopaus, terdapat 
penurunan aras estrogen yang mengakibatkan kehilangan tulang dan patah tulang. Pembentukan tulang dikawal oleh 
hormon yang berbeza. Dalam ulasan kepustakaan ini, kami menyerlahkan beberapa laluan isyarat seperti RANKL/
RANK, apoptosis dan Wnt/β-catenin serta fitoestrogens yang terlibat dalam metabolisme tulang. Isyarat RANKL/RANK 
bertanggungjawab mengawal pembentukan dan pengaktifan osteoklas multinukleus daripada prekursor mereka yang 
terlibat dalam proses pembentukan semula tulang yang normal. Apoptosis mengawal perkembangan, pertumbuhan 
dan penyelenggaraan tisu tulang. Laluan Wnt adalah sasaran farmakologi yang penting untuk ubat anabolik tulang 
dan penemuan masa depannya. Di dunia hari ini, banyak ubat-ubatan herba digunakan untuk merawat osteoporosis 
Osteoporosis: Possible menopaus kerana produk ini mengandungi fitoestrogen. Fitoestrogen mempunyai struktur seperti 
estrogen yang mempengaruhi metabolisme tulang. Fitoestrogen memberikan kesan terapeutik yang lebih baik dalam 
mengurangkan RANKL, osteoklastogenesis, penanda inflamasi dan meningkatkan penanda osteogenik dalam sel-sel tulang 
atau pun osteoblas. Kami membincangkan mekanisme tindakan beberapa fitoestrogen seperti genistein, daidzein dan 
equol yang bermanfaat untuk kesihatan tulang. Daidzein meningkatkan pertumbuhan osteoblas melalui peningkatan 
ekspresi BMP dalam sel osteoblas primer dan ia adalah agen antiosteoporotik yang berpotensi. Genistein juga mempunyai 
harta antioestrogenik berdasarkan daya saingnya yang kompetitif kepada reseptor yang sama seperti oestradiol. Equol 
mengawal kehilangan tulang melalui hemopoiesis dan penghasilan sitokin inflamasi. Oleh itu, fitoestrogen boleh 
digunakan sebagai agen osteoperlindungan untuk rawatan osteoporosis selepas menopaus.
Kata kunci: Estrogen; farmakologi; patah tulang; selepas menopaus; rawatan
INTRODUCTION
OSTEOPOROSIS
Osteoporosis is a common geriatric disease found in 
post-menopausal women, globally (Wade et al. 2014). 
Osteoporosis was reported to affect approximately 28 
million Americans and the costs were estimated about $14 
billion a year (Watts 1999). A recent study reported 200 
million people suffering from osteopororis worldwide, 
with 1 in 3 women over the age of 50 years and 1 in 5 men 
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predicted to suffer in their lifetime (Sözen et al. 2017). The 
clinical outcome and cost incurred for treatment of such 
disease warrants immediate attention on individuals who 
have high risk of developing the disease. According to 
research studies, the risk factors involved for osteoporotic 
fractures are low peak bone mass, disturbances in hormone 
level, consumption of drugs like glucocorticoids, smoking, 
decrease in physical activity, less intake of calcium and 
vitamin D, ethnic race, decreased size of the body, and 
history of fracture (Lane 2006). Another recent study 
identified risk factors for osteoporosis and these include 
underweight, high alcohol intake, nicotine use, liver 
disease, inflammatory joint disorders, diabetes mellitus, 
hyperthyroidism and use of medications (Christian et 
al. 2015). It was also reported that Asians have negative 
attitude towards calcium and vitamin D rich foods and 
supplements due to lactose intolerance, lack of motivation 
from the family and change in taste (Chan et al. 2018). 
Aging also reduces bone mineral density thereby 
predisposing to osteoporosis (Idrus et al. 2018).
 The main features of osteoporosis include bone loss, 
disturbance in the bone metabolism and damage to the 
trabecular histology of the bone, and these are associated 
with menopause (Jin et al. 2018). In osteoporosis, the bone 
becomes brittle and fracture occurs easily. Osteoporosis 
is considered as a silent disease but if a fracture occurs, 
it may give rise to chronic pain, disability, dependence 
on others, decrease the quality of life, and an increase in 
mortality cases (Lee et al. 2013). According to research 
reports, under-diagnosis of osteoporosis (Greenspan et 
al. 2012) and the unique opportunity to initiate bone 
modulating therapies prior to any osteoporotic fracture is 
usually missed in up to 84% of cases involving osteoporotic 
fractures (Smith et al. 2004). In many cases, osteoporosis 
remains undiagnosed and undertreated (Bliuc et al. 2013). 
Osteoporosis is related to the endocrine system of the body. 
In post-menopausal state, there is decrease in the hormones 
including estrogens and bone loss is observed. Decrease 
in the bone density is considered to be the most important 
risk factor for osteoporosis (Watts 1999). The National 
Osteoporosis Foundation recommended bone density tests 
for all women aged over 65 and or even earlier (close to 
the time of menopause) for women who have risk factors 
or who were considering treatment (Watts 1999). The 
utmost need is to provide early diagnosis and treatment 
and avoid any fracture which may increase the morbidity 
and mortality.
CHANGES IN THE BONE STRUCTURE                           
OCCURRING DURING OSTEOPOROSIS
Bone is a connective tissue comprising cells, fibers and 
extracellular matrix. As mineral deposits in the bone, it 
gets calcified. There is presence of mostly collagen which 
is a protein and provides the soft framework whereas 
the mineral calcium phosphate adds to the hardness and 
strength of the bone. The inorganic components of the 
matrix are mainly composed of calcium and phosphate 
and it is found in the form of hydroxyapatite crystals. The 
collagen fibers are coarse along with the hydroxyapatite 
crystals and it forms the basis of hardness, durability and 
strength of the bone.
 The cells which are found in the bone include 
osteoclasts, osteoblasts and osteocytes. Normally, a balance 
exists between the action of osteoblasts and osteoclasts. 
It should be kept in mind that changes in osteoclast 
population leads to an imbalanced resorption activity, 
which results in increased porosity of the bone (Yahaya et 
al. 2018). In post-menopausal state, there is deficiency of 
estrogen. In osteoporosis, the actions of osteoclasts (bone 
removing cells) are more active than the osteoblasts (bone 
forming). Hence, bone is removed faster than its formation. 
As a result, there is much bone loss. 
 Trabecular and cortical bone microanatomy play a 
vital role in providing mechanical strength to the bone. 
Cortical bone is the solid outer layer around the bone and 
comprises dense and parallel arrangement, concentric 
layers, and lamellar units which are known as osteons. 
The cortical bone is solid and compact. The osteons are 
nourished and connected to each other by Haversian system 
and Volkmann’s canal as well as canaliculi (Seeman 2006). 
The periosteum is located on its outer surface while on the 
inner surface, it is lined by the endosteum. On the other 
hand, trabecular or spongy bone exhibits a typical network 
of lamellar bone plates and rods. The structure of trabecular 
or spongy bone resembles a ‘honeycomb structure’. In 
osteoporosis, both cortical bone and the trabecular bone 
loss is a common feature. The bones become brittle and 
fracture occurs easily.
GROWTH AND DEVELOPMENT OF LONG BONE
At the fourth week of embryonic development, the 
cartilage is formed. The skeleton which is primarily 
made up of cartilage, possess no minerals. As the foetus 
grows, the cartilage is gradually replaced with osteoblasts 
and osteoclasts and then later on, ossification begins. 
Osteoblasts serve as the main important event in the 
bone formation during normal physiological process of 
bone turnover. Osteoblasts stimulate bone growth and 
facilitate bone resorption by regulating the osteoclasts 
which produces two different cytokines i.e. the receptor 
activator of NF-kB ligand (RANK-L) and osteoprotegrin 
(OPG), with the former promoting and the latter blocking 
the osteoclast activity, respectively (Marriott 2004). 
Osteoclasts are highly specialized multinucleated cells 
that resorb bone or invade mineralized tissue in a regulated 
manner. Osteoclasts dissolves the inorganic and the protein 
components of the bone matrix (Teitelbaum 2007).
 There are two types of ossifications which include 
intramembranous and endochondral ossification. Both 
chondrocytes and osteoblasts originate from the common 
osteochondro progenitor cells. Bone growth occurs due 
to two major ossification processes i.e. endochondral 
ossification and intramembranous ossification, and these 
involve chondrocytes and osteoblasts. Formation of 
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chondroclast/osteoclast is influenced by receptor activator 
of nuclear factor-kappa B ligand (RANKL), which is 
secreted from the osteoblasts and bone marrow stromal 
cells. In intramembranous ossification, the mesenchymal 
tissue is directly converted into bone tissue. The process 
occurs primarily in the flat bones at the eighth week 
of intrauterine life and completed at the age of two 
years. In endochondral ossification, mesenchymal cells 
differentiate into chondrocytes which subsequently 
becomes hypertrophic and die by apoptosis. With the 
gradual death of cartilage cells, there is replacement by 
the differentiated osteoblasts.
 Bone growth can also be classified into interstitial 
and appositional growth. In interstitial growth, the 
epiphyseal plate (cartilage) is replaced by bone and results 
in lengthening whereas appositional growth results in 
increase in the width (diameter) of a bone. Appositional 
growth occurs when osteoblasts located beneath periosteum 
secrete bone matrix on the bone surface and osteoclasts 
located on the endosteal surface remove the bone. 
HORMONAL REGULATION OF BONE GROWTH 
In the younger age period, the growth of bones is widely 
controlled by growth hormones such as thyroid hormones 
and sex hormones and these include testosterone and 
oestrogen. At puberty, the closure of the epiphyseal plates 
and cessation of the longitudinal growth of the bone is 
due to the sex hormones. Hence, hormonal therapy can 
influence bone growth.
 In the light of hormonal influence towards bone 
growth or bone loss, there is much concern regarding the 
exposure to environmental oestrogenic chemicals towards 
bone loss. The osterogenic chemicals negatively affected a 
number of human health disorders i.e. testicular carcinoma, 
precocious puberty, decrease sperm count, hypospadias, 
and cryptorchidism including bone metabolism (Carlsen 
et al. 1993).
 Bone homeostasis is due to a dynamic balance between 
bone remodeling and bone resorption by osteoblasts and 
osteoclasts, respectively (Seeman & Delmas 2006). In 
bone remodeling, there is synthesis of organic matrix 
by osteoblasts, and bone resorption by osteoclasts. This 
equilibrium is controlled by different physical parameters 
(i.e. mechanical stimulations) and numerous polypeptides 
(includes hormones, cytokines). Any disturbance between 
these effectors leads to bone abnormalities which is 
characterized by the decrease (osteoporosis) or increase 
(osteopetrosis) in the bone mass. 
 Osteoblasts and osteoclasts comprise of metabolic 
cells. Estrogen, progesterone and androgen act as important 
regulators in the bone metabolism. Sex hormones are 
responsible for maintaining bone function and mineral 
homeostasis during reproduction. Deficiency in certain 
sex steroids has an effect on the bone health and its 
metabolism (Van Pottelbergh et al. 2004). It is noteworthy 
to mention that RANKL is important for the formation of 
osteoclasts. Increased bone resorption in sex hormones 
deficiency is also related to the RANKL expression (Saika 
et al. 2001). There is substantial scientific evidence to show 
that sex steroids regulate the RANKL-OPG axis in the bone 
microenvironment, and the relative contribution of immune 
cell-derived versus mesenchymal cell-derived RANKL was 
poorly defined (Streicher et al. 2017).
 We highlight the effect of phytoestrogen on bone 
health and explain how the changes in hormonal action 
by environmental chemicals causes disruption to the bone 
metabolism. There are several research reports, which 
are still controversial. There are also unexplained queries 
related to the factors influencing the bone metabolism or 
bone health. In general, oestrogen is considered as a potent 
bone resorption inhibitor and if there is any disturbance in 
its hormonal level, it causes bone loss or osteoporosis in 
any individual.
DIFFERENT PATHWAYS WHICH ACT ON THE BONE 
METABOLISM RANKL/RANK SIGNALLING PATHWAY
The receptor activator of nuclear factor-κB ligand 
(RANKL) plays an important role in the regulation of the 
bone resorption (Thomas & Dong 2006). RANKL/RANK 
signalling is responsible for regulating the formation 
and activation of multinucleated osteoclasts from their 
precursors which is responsible for the survival of normal 
bone remodelling. RANKL acts along with osteoprotegrin 
(OPG) to prevent excessive bone resorption. OPG binds 
to the RANKL and prevents the binding from its own 
receptor, RANK. Previous research studies showed that 
RANKL/RANK signalling is also essential for lymph node 
formation and mammary gland lactational hyperplasia. 
OPG and RANKL are considered as members of a ligand-
receptor system that controls osteoclast differentiation 
and bone resorption (Yasuda et al. 1998). RANKL not only 
activates mature osteoclasts but also mediates the process 
of osteoclastogenesis in the presence of M-CSF (Kong 
et al. 1999). Soluble and membranous form of RANKL 
is expressed by preosteoblastic cells but their specific 
receptor RANK is located on the osteoclast progenitor cells 
(Lacey et al. 1998). This interaction is crucial absence 
of RANKL which is unable to produce osteoclasts. In this 
system, OPG, a decoy receptor, produced by osteoblasts 
prevents RANKL from binding to its own receptor. It also 
inhibits the osteoclasts formation and downregulates 
the RANKL signalling (Tsuda et al. 1997). Although the 
presence of OPG inhibits the process of osteoclastogenesis, 
excess OPG results in severe osteopetrosis and decreased 
formation of mature osteoclasts (Simonet et al. 1997). 
In contrast, absence of OPG results in osteoporotic state 
(Mizuno et al. 1998). OPG improves the bone cells by 
inhibiting differentiation, suppressing activation, and 
inducing apoptosis of mature osteoclasts (Theill et al. 
2002). Hence, bone remodelling is mainly under the control 
of RANKL/OPG.
 RANKL and OPG are found in different tumour 
cells. Soluble RANKL was produced by the prostate 
cancer cells in humans after being injected to SCID mice 
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(Zhang et al. 2001). The tumour cells which expressed 
RANKL were relatively higher in all bone metastases. 
Immunohistochemical findings showed positive RANKL 
staining in primary benign and malignant tumours of the 
bone and the bone metastases (Good et al. 2002). These 
research findings proved that increased RANKL expression 
was found in the bone tumour cells. As bone remodelling 
is the result of activity of osteoblast and osteoclast, 
pathological bone loss is due to a disturbance in the 
mechanism. Since its discovery, the RANKL/OPG system 
in osteoclast showed the pivotal role played by RANKL/
OPG system between osteoblasts and osteoclasts (Theill 
et al. 2002). The ratio of RANKL and its natural inhibitors 
OPG, is increased in severe conditions where there is bone 
loss. OPG stops the binding between RANKL and RANK, 
thereby playing an important role as the major inhibitor of 
osteoporosis. The RANKL/OPG ratio is the main mechanism 
which is involved in the pathogenesis of glucocorticoid-
induced osteoporosis (Chiodini et al. 1998).
 Thus, the facts related to the compensatory role of 
OPG on RANKL are well justified. The positive expression 
of RANKL in osteoclasts is due to an internalization of 
this ligand following binding to its specific receptor 
RANK, found on the cell membrane. The presence of 
inflammatory macrophage polykaryon which is deficient 
in RANK expression explains the heterogeneity in response. 
OPG has a highly basic heparin binding domain which 
makes interactions with heparin and heparan sulfates 
possible and this provides the scientific evidence of a 
new control mechanism for biological activity of the 
OPG. Proteoglycans which are expressed on the osteoclast 
membrane account for the internalization of OPG alone or 
are associated with RANKL into the osteoclasts. The serum 
levels of RANKL are increased in all patients with bone 
diseases (Terpos 2003). Interestingly, the RANKL/OPG ratio 
also correlates with markers of bone resorption and bone 
disease. 
 BPA suppresses RANK expression of osteoclasts in 
mRNA RT-PCR. The exposure with BPA for 24 h consistently 
downregulated one of the RANKL-induced transcription 
factors, NFATc1, and other signalling factors, such as MAPK, 
ERK, and AKT (Hwang et al. 2013). The dose of BPA (0.5, 
2.5 and 12.5 μM) was observed on bone marrow cells 
isolated from the femur and tibia bones of 5-week-old 
BKW mice and RAW264.7 mouse monocyte/macrophage 
cell line (Hwang et al. 2013; Martin & Sims 2005). A study 
conducted on mammary glands of the animals exposed to 
BPA, showed significant Wnt-mRNA and RANKL expression 
in BPA (6 μg/kg-bw/d) exposed animals. Consequently, the 
animals showed an increase in the progesterone expression 
(Martin & Sims 2005). However, the direct effect of BPA 
on RANKL expression in bone metabolism still remains 
unknown. 
 Oestrogen (E2) downregulates osteoclast formation by 
decreasing interleukins production (IL-1,-6 and TNF) and 
cytokines that augment RANKL production from osteoblasts. 
E2 also decreases the ‘response of mature osteoclasts to 
RANKL by deactivating the Jun N-terminal kinase (JNK). 
JNK, a mitogen activated protein kinase, is activated during 
binding of RANKL of its own receptor RANK’ (Ayyanan et 
al. 2011). ‘E2 suppressed the ability of RANKL to induce 
the activation of JNK1 by decreasing the levels of c-Fos 
and c-Jun’ (Srivastava et al. 2001). Hence, E2 checks 
osteoclastogenesis by decreasing the responsiveness of OC 
precursors to the osteoclastogenic cytokine RANKL. BPA 
mimics the oestrogenic effects but it interacts differently 
on the ligand binding domain of oestrogen receptors. As a 
result, it reverses the effect of oestrogen by increasing the 
RANKL expression and stimulates the osteoclastogenesis. 
BPA inhibits bone mineralization and bone mass formation 
by blocking both osteoblasts and osteoclasts differentiation 
(Hwang et al. 2013). 
APOPTOSIS PATHWAY
Bone is a mineralized and dynamic tissue, affected by 
different kinds of stimuli during its remodelling process 
(Sims & Walsh 2012; Stains & Civitelli 2005). The 
stimuli from endocrine, paracrine, and autocrine directly 
affect the cell to cell communications through gap 
junctions (Stains & Civitelli 2005), or through the hemi-
channels (Watkins et al. 2011). The gap junctions and 
hemichannels contribute to the survival and death of the 
cell, i.e. apoptosis. Cell apoptosis are related to different 
physiological and pathological conditions. Apoptosis 
regulates the development, growth and maintains the bone 
tissues (Giner et al. 2013), but it is a cause of worry as the 
bone tissue is inactive at cellular level (Hughes & Boyce 
1998). In physiological conditions like aging, the risk of 
apoptosis is quite high and this results in the decrease in 
the formation of osteoblasts and bone (Almeida 2012).
 ‘The key adhesion molecules needed for bone 
cell development and apoptosis is the caspase which 
plays an important role in osteoblast apoptosis’ (Miura 
et al. 2004). ‘Apoptosis in osteoblast is influenced by 
extracellular signal-regulated kinase (ERK), mitogen-
activated protein kinases (MAPK), JAK2 and Fas’ (Liu et 
al. 2013, 2008). Factors like oxidized lipids which inhibit 
osteoblast differentiation through reactive oxygen species 
(ROS)-independent mechanisms and induce apoptosis in 
osteoblasts. Osteoblasts apoptosis is an important factor 
in stimulating bone loss compared to the osteocytes and 
osteoclasts.
Wnt/β-CATENIN SIGNALLING PATHWAY
The Wnt/β-catenin signalling pathway is a well-known 
pathway in normal organogenesis occurring during fetal 
development. It has an important role in the cellular 
processes including cell survival, cell proliferation, and cell 
fate specification (Bakre et al. 2007). The involvement of 
Wnt/β catenin signalling pathway in bone metabolism is an 
area of interest to researchers. Wnts, a family of 19 secreted 
glycoproteins, binds to complexes receptor including low-
density lipoprotein receptor-related protein (LRP)-5/6 and 
frizzled proteins. Subsequently, the intracellular cascade 
stabilizes β-catenin, leading to its translocation into the 
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nucleus and accentuates the gene expression. Wnt pathway 
is a potential pharmacological target for bone anabolic 
drug discovery. 
 Wnt, rich in cysteine, and according to description 
it ‘forms a family of 19 highly conserved secreted 
signalling molecules which plays an important role in the 
osteoblastogenesis/bone formation’ (Pandur et al. 2002). 
The number of Wnts involved in the bone formation is yet 
to be outlined. ‘Wnt1, Wnt3a activates the canonical Wnt 
signalling pathway in formation of Wnt frizzled proteins 
and LRP5 or LRP6 receptors’ (Tamai et al. 2000). ‘The non-
canonical Wnt5a class binds to frizzled proteins, activates 
heterotrimeric G proteins and increases intracellular 
calcium via protein kinase C-dependent mechanisms or 
induces cytoskeleton formation’ (Veeman et al. 2003).
 Known members of the LDL receptor family serve 
cell signalling functions in various tissues and cell types 
(Kanazawa et al. 2004). Human low-density lipoprotein 
(LDL) receptor–related proteins (LRP5 and 6) are 
homologous. Wnts are lipid-modified and it acts on the 
LRPs and promote the signalling. LRP5/6 functions along 
with Fz to stimulate the catenin pathway in response to 
different Wnt proteins (Brown et al. 1998). Wnt pathway, 
regulates the expression of certain transcription factors, 
such as Runx2, Osterix and dlx5 (Bennett et al. 2005). In 
addition, Wnt signalling up-regulates Runx2 transcription 
in both osteoprogenitor cells and embryonic mesenchymal 
cells while promoting the entry of mesenchymal cells 
into the osteogenic lineage for both endochondral and 
intramembranous bone formation (Gaur et al. 2005). On 
the other hand, Wnt3a controls osteoclastogenesis through 
Runx2, the down-regulation of RANKL expression and 
induction (Gaur et al. 2005). These reciprocal changes 
in RANKL and OPG expression mediate the effect of Wnt 
signalling on osteoclast differentiation in vivo. A strong link 
between Wnt and osteoblastogenesis through interaction 
with the heterodimer Smad/Runx2 was also suggested. 
Cbfa1 (Core binding factor a1)/Runx2 (runt related 
transcriptional factor 2) determines the osteoblast lineage 
from multi-potent mesenchymal cells, induces osteoblastic 
differentiation at the early stage and inhibits it at the late 
stage (Banerjee et al. 1997; Komori et al. 1997). Moreover, 
Runx2 was reported to induce alkaline phosphatase (ALP) 
activity, expression of bone matrix protein genes and 
mineralization in in vitro osteoblastic cell line (Ducy et al. 
1997). The Wnt cascade activates Src/ERK, AKT proteins 
and promotes anti-apoptotic effect. The Wnt induced 
Runx-2 transcription regulates the expression of RANKL 
and OPG. The Ca2+ mediated non-canonical Wnt pathway 
promotes osteoblast differentiation. Studies performed 
on transgenic mice showed that osteoblast lineage was 
targeted to increase Wnt signalling, and it resulted in 
increased osteoprotegerin (OPG) production and decreased 
osteoclast formation (Glass et al. 2005; Thirunavukkarasu 
et al. 2000).
 The Wnt/β catenin signalling pathway regulates 
osteoclast formation by suppressing the RANKL expression 
and/or up-regulating the OPG expression. OPG is a decoy 
receptor produced by osteoblasts that binds to the RANKL 
and inhibits osteoclastogenesis (Bakre et al. 2007). An 
important concern is whether the Wnt/ β-catenin signalling 
is modulated by ROS. The oxidative stress condition alters 
the link of β-catenin with its nuclear partners, which 
include LEF, forkhead box transcription factors (FoxOs), 
hypoxia-inducible factor (HIF-1), and p53 (Taylor et al. 
2011). Depending on the duration of the oxidative stress, 
cellular process such as cell survival or cell death varies. 
Recently, molecular studies demonstrated that Wnt/β-
catenin signalling alters the cell survival program and 
promotes cell death (Kawamoto et al. 2012). Wnt is a major 
mediator of osteoblastogenesis and osteoclastogenesis and 
these were observed both in vitro and in-vivo.
ROLE OF PHYTOESTROGENS
Phytoestrogens (PEs) are naturally occurring plant 
products. They mimic or modulate endogenous hormones 
like oestradiol by exerting the oestrogenic or/and anti-
oestrogenic effects (Setchell et al. 2001). They are 
present in different fruits, vegetables, and whole grains. 
They belong to the Leguminosae family (Dixon 2004; 
Michel et al. 2013), and they are found in soy/soy protein, 
red clover, kudzu, hops, licorice, rhubarb, yam, and 
chasteberry (Hajirahimkhan et al. 2013). ‘PEs are divided 
into three (3) main classes: Phytoestrogens (genistein, 
daidzein, formonetin, biochanin A, and equol), lignans 
(enterolactone, enterodiol, pinoresinol, lariciresinol, 
secoisolariciresinol, matairesinol), and coumestans (e.g. 
coumestrol)’ (Cornwell et al. 2004; Ibarreta et al. 2001). 
Phytoestrogens are also found in soybeans, lignans in 
flaxseed, and coumestans in clover, alfalfa and soybean 
sprouts. It was mentioned that phytoestrogens are the 
main active compounds in soy/soy protein which possess 
multiple therapeutic effects (Chen et al. 2003).
 Depending on the geographical location of different 
nations and their cultures, the intake of phytoestrogens 
varies and Malaysia is an ideal example (Figure 1). 
In the Asian population, approximately 20-50 mg of 
phytoestrogens are consumed daily (Fritz et al. 2013; 
Mense et al. 2008). There are epidemiological studies 
which suggested the recommended dose of phytoestrogens 
in reducing the risk of cardiovascular diseases in 
postmenopausal women (Moreira et al. 2014). However, 
the mechanism of action of phytoestrogens towards bone 
loss still debatable. It is noteworthy to mention that PE 
serves as an oestrogen antagonist by blocking the potent 
endogenous oestrogen to bind its own receptor. Several 
literature provide conflicting reports on the mechanism 
of action of phytoestrogens (Paterni et al. 2014; Rietjens 
et al. 2013; Younes 2011). The different research findings 
on the effect of phytoestrogens, depends on their dose, 
class, presence or absence of endogenous oestrogens and 
oestrogen receptors (ERα and ERß) (Benassayag & Perrot-
Applanat 2002).
 Although there are several studies which outlined 
the positive effect of herbs or compounds against bone 
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loss, the role of phytoestrogens in regulating the disease 
was not summarised, to date. In the present review, we 
focused mainly on the mechanism of phytoestrogens such 
as genistein, daidzein and equol in improving the bone 
health. The effect of these three bioactive compounds on 
bone health were further discussed in detail.
DAIDZEIN 
Daidzein (4′, 7-dihydroxyisoflavone, C15H10O4) is natural 
phytoestrogen which belongs to the family of diphenolic 
compounds and has structural similarity to natural and 
synthetic oestrogen (Figure 2) (Lampe 2003). Daidzein 
in the bound form ‘daidzin’, becomes inactive. It is found 
in leguminous plants such as soy and mung bean. It is the 
second most abundant phytoestrogen found in soy, next 
to genistein. Asians were reported to consume 15-50 mg 
of daidzein/day, compared to the Western individuals who 
consumed approximately 1-2 mg (Froyen et al. 2009). 
Interestingly, in countries like Japan where soy intake 
is quite high, there is approximately 85% lower rate of 
health ailments as comparted to that in the West. It is 
commonly used as a bioactive compound in traditional 
Chinese medicine Gegen (Wang et al. 2003). According 
to published literature, it has been used effectively in the 
treatment of fever, acute dysentery, diarrhoea, diabetic 
conditions, cardiac problems and liver injury (Wong et 
al. 2011). Recent research reports show that following 
knee surgery, daidzein was also even able to reduce intra-
articular adhesion around the knee (Liu et al. 2017).
 Daidzein exhibits a chemical structure which is very 
similar to oestrogen. It either replaces or interferes with 
the oestrogen and the oestrogen-receptor (ER) complex. 
Therefore, daidzein attenuates the oestrogen related 
diseases which includes breast carcinoma, osteoporosis 
and different cardiovascular diseases (Vitale et al. 2013). 
In addition, diadzein has positive effects on non-oestrogen 
related diseases which include properties such as anti-
inflammatory, anticancerous and has a role in oxidative 
stress related diseases and protection of skin and the nerves. 
Diadzein regulates the immune system (Masilamani et 
al. 2012), scavenging oxygen free radicals and inhibiting 
VSMCs proliferation. A recent research study showed that 
daidzein showed an increase in body mass, increase in 
trabecular bone mass and decreased the bone turnover 
rate in severe andropause animal models (Ajdžanovic et 
al. 2018).
 Few metabolites of daidzein exhibit a similar pattern. 
Equol (C15H14O3) is a metabolite of daidzein which is 
commonly present in the soy/soy protein (Törmälä et al. 
2008). Soy phytoestrogens are capable to biotransform 
into potent oestrogenic metabolite, equol, enhancing its 
actions. Equol has greater affinity for oestrogen receptors, 
exhibits unique anti-androgenic properties, and has potent 
antioxidant actions (Kang et al. 2007). Equol is metabolized 
from daidzein in the human body with the help of intestinal 
flora. This compound increases the bone mineral density, 
affects the vasomotor symptoms, decreases the level of 
low density lipoprotein and also improves the endothelial 
dysfunction (Cassidy & Albertazzi 2006; Sirtori 2001).
 Daidzein is a potential antiosteoporotic agent which 
possesses both osteogenic and anticancer activities (Adjakly 
et al. 2013; Chen et al. 2015). Daidzein was reported to 
enhance osteoblast growth via the upregulation of BMP 
expression in primary osteoblast cells (Jia et al. 2003). 
Daidzein promoted cell differentiation and mineralization 
in mouse osteoblast-like MC3T3-E1 cells (Ge et al. 2006). 
The effect of Daidzein on osteoblasts were mediated 
through the oestrogen related beta (ER-beta) pathway 
(De Wilde et al. 2004). However, the detail mechanism 
concerned with antiosteoporosis properties of Daidzein and 
the effected pathway is still being debated by researchers. 
FIGURE 1. Schematic diagram to show that the tendency to have osteoporosis is more in 
the Western population compared to Malaysian population. This is attributed to more 
consumption of local dietary food rich in phytoestrogens in Malaysia
FIGURE 2. Chemical  structure of Daidzein (Lampe JW 2003)
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It was observed that Daidzein increased the cells viability, 
ALP activity, osteocalcin synthesis and BMP-2 expression 
in primary osteoblast cells (Jia et al. 2003). According to 
earlier research findings, Daidzein improved the ostegenic 
genes expression such as ALP, Smad1, Runx2, Osx, Col I, 
in human bone marrow-derived mesenchymal stem cells 
(HBMSCs) (Strong et al. 2014). Daidzein stimulated the 
osteoblast differentiation and mineralisation in MC3T3-E1 
cells as well as in OCT1 cells (Ge et al. 2006). The effect 
of Daidzein on osteoblast differentiation was mediated by 
the expression of BMP-2 (Jia et al. 2003). Moreover, Dz 
inhibited osteoclast differentiation by increasing ER-alpha 
expression (Babu et al. 2012; Palacios et al. 2005).
GENISTEIN 
Genistein (40, 5, 7-trihydroxyisoflavone, C15H10O5) is 
natural flavonoid of Leguminoseae plants, and it is a 
phytoestrogen which exhibits dual agonist and antagonist 
oestrogenic properties (Figure 3) (Danciu et al. 2012). 
Genistein was used for the prevention and treatment of 
chronic diseases. Genistein exhibits vasodilator, anti-
thrombotic and anti-atherosclerotic effects through various 
mechanisms (Lee 2006; Messina et al. 2006; Williamson-
Hughes et al. 2006). Genistein bears structural similarities 
with the chemopreventive agent tamoxifen, and (Marrian 
& Haslewood 1932) equol, a dietary isoflavone formed 
by gastrointestinal flora (Kwon 2014). In addition to the 
oestrogenic activities, genistein also contributes to the 
anti-oestrogenic activities by competitively binding to 
the same receptors as oestradiol (Kwon 2014). Genistein 
was effectively used in the treatment of atherosclerosis. 
Genistein administered in the dose of 0.1 μmol/L improved 
the endothelial nitric oxidase synthase (eNOS) uncoupling 
related to sirtuin-1 pathway in ox-LDL-induced human 
umbilical vein endothelial cells (HUVECs). It was reported 
that eNOS uncoupling was a major factor which caused 
endothelial dysfunction in atherosclerosis (Zhang et al. 
2016). Moreover, genistein was reported to decrease the 
superoxide production and NOX4 expression, increase the 
ratio of BH4/BH, the expression of GTP cyclohydrolase 1 
(GCH1) and dihydrofolate reductase (DHFR) (Babu et al. 
2012). 
 Phytoestrogens mainly found in soybean was shown to 
improve bone loss in individuals in inhabitants of Eastern 
part of the globe and its effect on bone metabolism was 
solely due to the action of the soybean phytoestrogens 
which included diadzein, genistein and equol. Both, 
EDC and phytoestrogens bind to the oestrogen receptors. 
However, it is most likely to differ with regard to types of 
oestrogen receptors. BPA acts more on the non-classical 
oestrogen receptor γ, while phytoestrogens trigger the 
classical oestrogen (α and β) pathway. This difference 
in binding is probably due to the antagonising effect on 
bone health. However, less is known on the fact whether 
the phytoestrogens can protect against BPA induced bone 
loss.
EQUOL
Equol, a metabolite of diadzein, is an important isoflavone 
of soybean (Figure 4). It is considered to be more 
biologically active comparted to other isoflavone aglycone 
(Setchell & Clerici 2010; Yuan et al. 2007). Researchers 
observed the metabolism of isoflavones and biological 
actions of equol in detail (Setchell et al. 2002). The 
oestrogenic effects of equol were documented following 
discovery of the first oestrogen receptor (ER). Equol binds 
to ERs and induces transcription (Chang et al. 1975). Equol, 
a chiral molecule, is found as enantiomers R-equol and 
S-equol. It was shown that S-equol, has relatively high 
affinity for ERs compared to R-equol (Saitoh et al. 2004). 
Equol was reported to inhibit bone loss in ovariectomised 
mice and rats (Fujioka et al. 2004; Kolios et al. 2009; 
Ohtomo et al. 2008). In an in vitro study, equol inhibited 
the osteoclastogenesis induced by oestradiol (Ohtomo 
et al. 2008). Epidemiologic studies showed that high 
equol producers often reduce the risk of breast cancer 
compared to the low producers (Adlercreutz et al. 2002). 
Postmenopausal high equol producers had decreased 
bone loss compared to the low producers (Vatanparast 
& Chilibeck 2007). A recent research study showed that 
equol was able to improve the bone and cardiovascular 
parameters in middle-aged Japanese females (Yoshikata 
et al. 2018). 
 It is pertinent to mention that S-equol inhibited 
decrease in the bone mineral density of postmenopausal 
women without causing any major side effects (Tousen 
et al. 2011). Equol was shown to prevent bone loss in the 
ovariectomised mice (Fujioka et al. 2004). Equol is very 
similar to selective ER modulators while preventing bone 
loss without oestrogenic activity. 
 It was observed that equol acted on bone loss and 
changes in immune system-related genes caused by 
deficiency of oestrogen. Equol regulates bone loss via 
hemopoiesis and inflammatory cytokine production. It 
promotes the process of proliferation and differentiation of 
primary cultured osteoblasts by increasing the osteoblast 
differentiation markers, ALP and osteocalcin and blocking 
the ER antagonist. It was suggested that equol has an 
action like ER agonist on the osteoblasts. Interestingly, 
the metabolic ability of equol is different among different 
races (Jou et al. 2008; Setchell et al. 2002). Hence, the 
controversial research findings of soy isoflavones in the 
management of osteoporosis or bone loss may be due to 
differences in the production and metabolism of equol in 
different individuals.FIGURE 3. Chemical structure of Genistein (Danciu et al. 2012)
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 The majority of studies reported beneficial effect 
of phytoestrogens on bone (Figure 5) but there are few 
studies which reported less effects. A past study reported 
that daidzein and equol slightly reduced but reduced the 
bone loss was certainly not significant (Tousen et al. 
2014). Another research study stated that genistein did 
not significantly reduce the serum osteoclacin compared 
to commercial oestrogenic compound against post-
menopausal osteoporosis (Miao et al. 2012). There are 
also reports of lack of favorable effects of genistein on 
the mineralization of bone and mechanical properties as 
seen in estrogen deficient animals (Sliwiński et al. 2009). 
Interestingly, a recent research study also showed that 
synergestic phytochemicals failed to protect bone loss in 
ovariectomised rats (Ambati et al. 2018).
TREATMENT OPTIONS IN                                                               
POST-MENOPAUSAL OSTEOPOROSIS
One of the mainstays of treatment in post-menopausal 
women is replacement of the bone loss. This has to be 
done in order to avoid the vertebral and non-vertebral 
(hip) fractures. Hormone replacement therapy is advised. 
Oestrogen replacement is the treatment of choice. Other 
hormones include progestin, progesterone, testosterone 
in different composition. Drugs such as alendronate, 
raloxifene, risedronate, 1-34 fragment of parathyroid 
hormone, and nasal calcitonin are advised for effective 
treatment (Delmas 2002). Adequate level of Calcium and 
Vitamin D has to be maintained. Treatment with estrogens 
checks the osteoclastic resorption and helps to conserve the 
bone mass (Al-Anazi et al. 2011). Anabolic hormones i.e. 
progesterone, stimulates osteoblastic activity of bone and 
the use of the combination of estrogen and progesterone 
decreases the risk of uterine cancers besides treatment of 
osteoporosis (Al-Anazi et al. 2011). Androgen replacement 
also increases the bone mass in the affected individual. All 
allopathic drugs are known to cause several side-effects. 
Hence, there is need to look for natural products which may 
be helpful for treating postmenopausal osteoporosis. One 
such potent natural product is phytooestrogen.
FIGURE 4. Chemical structure of Equol, a metabolite of Diadzein (Setchelo & Clerici 2010)
FIGURE 5. Figure showing the effect of phytoestrogen 
on Wnt/β catenin pathway in osteoblasts
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 The phytoestrogens are polyphenol compounds 
derived from plants and their structure resemble the 
steroid hormone 17-beta-estradiol. The source of these 
phytoestrogens may be from supplements or even soy 
based products. Soy isoflavones have similar structurally 
and functional to that of 17-beta-estradiol and it acts on 
osteoblasts and osteoclasts via genomic and non-genomic 
pathways to produce beneficial effects on bone metabolism, 
bone turnover markers, and mechanical strength of bones in 
the postmenopausal state (Atmaca et al. 2008). Isoflavones 
binds to estrogen receptors on the target cell surface and 
this may be helpful in the treatment of osteoporosis in the 
post-menopausal state.
CONCLUSION
The knowledge of different pathways leading to bone loss 
and bone metabolism is necessary for effective treatment 
of osteoporosis and its complications. Conventional 
drugs used for treatment for osteoporosis have several 
side effects including cancer. This opens the door to look 
for synthetic and natural products. Natural products have 
gained popularity because of easy availability, less cost, 
fewer side effects and patient compliance. Phytoestrogens 
have similar structure to estrogen and they can be used to 
treat estrogen deficiency state. Use of phytoestrogen may 
also be beneficial on uterus and other reproductive organs. 
It has to be considered that not all humans are capable 
of metabolising daidzein to equol. Hence, the role of 
phytoestrogens may also vary but in the majority of cases, 
metabolism occurs and phytoestrogens have a positive role 
in maintaining bone health. In the present review, we aimed 
to highlight the pathways and the phytoestrogens involved 
in bone metabolism. Further clinical trials are advised in 
future to ascertain the efficacy and long term benefits of 
natural products like phytoestrogens. 
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